Molnupiravir's authorisation was premature
- PMID: 35241455
- DOI: 10.1136/bmj.o443
Molnupiravir's authorisation was premature
Conflict of interest statement
Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The author declares no other interests. Further details of The BMJ policy on financial interests are here: https://www.bmj.com/sites/default/files/attachments/resources/2016/03/16-current-bmj-education-coi-form.pdf.
Comment in
-
Imbalance in baseline characteristics in molnupiravir trials.BMJ. 2022 Apr 26;377:o977. doi: 10.1136/bmj.o977. BMJ. 2022. PMID: 35473695 No abstract available.
-
Molnupiravir's authorisation should be re-evaluated after the Panoramic trial is reported.BMJ. 2022 Apr 26;377:o973. doi: 10.1136/bmj.o973. BMJ. 2022. PMID: 35474171 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources